MaxCyte, Inc. Dosing Begins in First Clinical Trial of MCY-M11 (4884D)
10 October 2018 - 5:00PM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 4884D
MaxCyte, Inc.
10 October 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
MaxCyte Commences Dosing in First Clinical Trial in Solid
Tumours
First patient dosed in Phase I clinical study to evaluate
MaxCyte's lead CAR therapeutic
in ovarian cancer and peritoneal mesothelioma
Gaithersburg, Maryland - 10 October 2018: MaxCyte (LSE: MXCT,
MXCR), the global cell-based medicines and life sciences company,
announced today that the first patient has been dosed in its Phase
I dose-escalation clinical trial in the United States with the
Company's lead wholly-owned chimeric antigen receptor (CAR)
therapeutic candidate, MCY-M11. The study is designed to evaluate
MCY-M11, a mesothelin targeting CAR, in individuals with
relapsed/refractory ovarian cancer and peritoneal mesothelioma.
"The initiation of patient dosing in our first clinical trial
with our lead CAR therapeutic candidate is a significant milestone
for MaxCyte, validating our streamlined manufacturing process for
clinical use," said MaxCyte CEO Doug Doerfler. "We are extremely
pleased to have very experienced investigators at two leading
clinical centers conducting this study in solid tumours. We believe
this clinical trial will further demonstrate the potential of our
proprietary CARMA(TM) (CAR therapeutic) autologous cell-therapy
platform to develop meaningful, targeted cell-based immune
therapies."
CARMA utilises messenger RNA (mRNA) as the delivery vehicle for
a CAR transfected into freshly isolated peripheral blood
mononuclear cells, allowing for rapid manufacture and delivery back
to the patient, without the need for a viral component or cell
expansion. The CARMA platform provides a cell therapy with
transient expression, enabling repeat dosing and with the potential
to reduce the cost and minimize adverse side-effects seen in
viral-based CAR therapies.
"In recent years we have seen tremendous progress in the
treatment of some types of cancer, but there remains a significant
need to explore novel treatments that may benefit patients," said
Claudio Dansky Ullmann, MD, MaxCyte Chief Medical Officer.
"Individuals with advanced and relapsed ovarian cancer or
peritoneal mesothelioma have limited effective therapeutic options
today. MCY-M11 is an exciting new approach with the potential to
improve outcomes for these patients. We look forward to the
continued progress of this first clinical study."
About the Phase I Clinical Trial
The multi-center, non-randomized, open label, dose-escalation
Phase I clinical trial will evaluate the safety and effectiveness
of intraperitoneal infusions of MCY-M11 in individuals with
platinum-resistant high-grade serous adenocarcinoma of the ovary,
primary peritoneum or fallopian tube, or individuals with advanced
peritoneal mesothelioma with recurrence after prior chemotherapy.
MaxCyte anticipates approximately 15 study participants will be
enrolled across the two clinical sites participating in the study
(the National Cancer Institute at the National Institutes of Health
(NIH) and Washington University at St. Louis). More information
about the study can be found at
https://clinicaltrials.gov/ct2/show/NCT03608618?term=maxcyte&rank=1.
About the CARMA (CAR Therapy) Platform
CARMA is MaxCyte's unique and proprietary CAR therapy platform
in immuno-oncology. The platform is used to develop CAR therapies
for a broad range of cancer indications. It offers the potential to
deliver autologous cell therapies across a wide range of targets
with a much quicker turnaround to the patient than traditional
autologous cell therapies, and with repeat dosing that may reshape
the endogenous immune system of these patients towards a more
effective antitumor response. More information on MaxCyte's CARMA
programme is available at https://www.maxcyte.com/car/.
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences
company applying its patented cell engineering technology to help
patients with high unmet medical needs in a broad range of
conditions. MaxCyte is developing novel CARMA therapies for its own
pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for
autologous cell therapy. In addition, through its core business,
the Company leverages its Flow Electroporation(R) Technology to
enable its partners across the biopharmaceutical industry to
advance the development of innovative medicines, particularly in
cell therapy, including gene editing and immuno-oncology. The
Company has placed its cutting-edge flow electroporation
instruments worldwide, with all of the top ten global
biopharmaceutical companies, has more than 55 partnered programme
licences in cell therapy including more than 25 licensed for
clinical use. With its robust delivery technology, MaxCyte helps
its partners to unlock the full potential of their products. For
more information, visit www.maxcyte.com
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Ryan McCarthy
Corporate Broking
James Stearns +44 (0)20 7886 2500
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCUKORRWKARRUA
(END) Dow Jones Newswires
October 10, 2018 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024